HR Execs on the Move

Oncternal

www.oncternal.com

 
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.oncternal.com
  • 12230 El Camino Real Suite 300
    San Diego, CA USA 92130
  • Phone: 858.434.1113

Executives

Name Title Contact Details

Similar Companies

Infinity Care Solutions

Infinity Care Solutions wants to take the time and trouble out of a normal pharmacy experience by not only providing you with traditional medications, but also offering you and your healthcare provider a choice. We know that no two patients are exactly the same and each requires specific knowledge and a team approach. It is our goal to meet this challenge head on. With our top-of-the-line, custom-made compounded products, and our impeccable customer service, our mission is for you to experience symptom relief like never before. Our pharmacy is built on a solid foundation of medical expertise and cutting edge pharmaceutical compounding methods that are unmatched, especially in the areas of topical hormone replacement therapy and topical pain medications.

Lundbeck

Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company`s products are targeted at disease areas such as depression, schizophrenia, Parkinson`s disease and Alzheimer`s disease. According to the World Health Organization, WHO, more than 700 million cases of psychiatric and neurological disorders are reported every year. These are serious and life-threatening diseases that affect the quality of life of the patients as well as of their relatives. As these diseases also involve major socio-economic costs, it is imperative for the general society that new and innovative pharmaceuticals are developed. Over the past 50 years, new pharmaceuticals have revolutionised the treatment options, but there remains a large unmet need for new and innovative therapeutics. Focus on R&D is the most important pillar in Lundbeck`s ambition to improve treatment for people living with psychiatric and neurological disorders. We are specialists in our area and have research facilities in Denmark and China, and more than 1,000 employees work in our R&D units. We cooperate closely with strategic partners all over the world, ensuring the best possible foundation for innovation and the development of new treatment solutions. Lundbeck employs approximately 5,300 people worldwide, 1,700 of whom are based in Denmark. We have employees in 55 countries, and our products are registered in more than 100 countries. We have production facilities in China, Denmark, France and Italy and research centres in Denmark and China.

Viatris

VIATRIS™ is a new kind of global healthcare company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer. By integrating the strengths of these two companies, including our global workforce of approximately ~45,000, we aim to deliver increased access to affordable, quality medicines for patients worldwide, regardless of geography or circumstance.

egb Advisors

egb Advisors is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Otsuka America

There are three Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis. Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is a basic research center investigating pharmacological compounds.